Medical evaluation of nephrolithiasis

Endocrinology and Metabolism Clinics of North America

Volumn 31, Issue 4, 2002, Pages 1031-1050

  Tiselius, Hans Göran ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMMONIA; AMMONIUM MAGNESIUM PHOSPHATE; APATITE; ASCORBIC ACID; CALCIUM OXALATE; CALCIUM PHOSPHATE; CARBONIC ACID; CORTICOSTEROID; CYSTINE; CYTOTOXIC AGENT; FUROSEMIDE; INDINAVIR; SILICATE; SODIUM; STRUVITE; SULFADIAZINE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; URIC ACID;

ANAMNESIS; BLOOD ANALYSIS; CALCIUM STONE; COMPUTER ASSISTED TOMOGRAPHY; CRYSTALLIZATION; CYSTINURIA; DIET THERAPY; DISEASE ASSOCIATION; HUMAN; NEPHROLITHIASIS; PRIORITY JOURNAL; PYELOGRAPHY; RECURRENT DISEASE; REVIEW; RISK FACTOR; STONE FORMATION; URIC ACID STONE; URINALYSIS; URINE PH; UROGRAPHY; UROLITHIASIS; CALCIUM INTAKE; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; FEMALE; MALE; METABOLISM;

CALCIUM OXALATE; CALCIUM, DIETARY; CYSTINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KIDNEY CALCULI; MALE; RISK FACTORS; URIC ACID;

EID: 0036895603     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(02)00027-0     Document Type: Review

References (114)

1. Dretler SP. The physiologic approach to the medical management of stone disease. Urol Clin North Amer 1998;25:613-22.
2. Sperling O. Uric acid nephrolithiasis. In: Wickham J, Buck AC, editors. Renal Tract Stone-Metabolic Basis and Clinical Practice. New York: Churchill Livingstone; 1990. p. 349-65.
3. Tiselius HG. Solution chemistry of supersaturation. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, editors. Kidney Stones - Medical and Surgical Management. Philadelphia: Lippincott-Raven Publishers; 1996. p. 33-64.
4. deVries A. Clinical management of uric acid lithiasis. In: Roth RA, Finlayson B, editors. Stones - Clinical Management of Urolithiasis. Baltimore (MD): Williams and Wilkins; 1983. p. 228-47.
5. Erwin C-YL, Nancollas GH. The crystallization and dissolution of sodium urate. J Crystal Growth 1981;53:215-23.
6. Marshall RW, Robertson WG. Nomograms for the estimation of the saturation of urine with calcium oxalate, calcium phosphate, magnesium ammonium phosphate, uric acid, sodium acid urate, ammonium acid and cystine. Clin Chim Acta 1976;72:253-60.
7. Joly D, Rieu P, Méjean A, Ganadoux MF, Daudon M, Jungers P. Treatment of cystinuria. Pediatr Nephrol 1999;13:945-50.
8. Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL. Clinical use of cystine supersaturation measurements. J Urol 2000;164:1481-5.
9. Sakahee K, Sutton RAL. Pathogenesis and medical management of cystinuria. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, editors. Kidney Stones: Medical and Surgical Management. Philadelphia: Lippincott-Raven Publishers; 1996. p. 1007-17.
10. Wall I, Tiselius HG. Studies on the crystallization of magnesium ammonium phosphate in urine. Urol Res 1990;18:401-6.
11. Tiselius HG. An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chem Acta 1982;122:409-18.
12. Tiselius HG. Aspects on estimation of the risk of calcium oxalate crystallization in urine. Urol Int 1991;47:255-9.
13. Tiselius HG. A simplified estimate of the ion-activity product of calcium phosphate in urine. Eur Urol 1984;10:191-5.
14. Brown CM, Ackermann DK, Purich DL. EQUIL 93: A tool for experimental and clinical urolithiasis. Urol Res 1994;22:119-26.
15. Finlayson B. Calcium stones: some physical and clinical aspects. In: Calcium Metabolism in Renal Failure and Nephrolithiasis. New York: John Wiley & Sons; 1977.
16. Györy AZ, Ashby R. Calcium salt urolithiasis - Review of theory for diagnosis and management. Clin Nephrol 1999;51:197-208.
17. Robertson WG. Measurement of ionized calcium in biological fluids. Clin Chim Acta 1969;24:149-57.
18. Werness PG, Brown CM, Smith LH, Finlayson B. EQUIL 2: A basic computer program for the calculation of urinary saturation. J Urol 1985;134:1242-4.
19. Azoury R, Robertson WG, Garside J. Observations on the in vitro and in vivo calcium oxalate crystalluria in primary calcium stone formers and normal subjects. Br J Urol 1987;59:211-3.
20. Grases F, Conte A. Urolithiasis, inhibitors and promoters. Urol Res 1992;20:86-8.
21. Hess B, Kok DJ. Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, editors. Kidney Stones - Medical and Surgical Management. Philadelphia: Lippincott-Raven publishers; 1996. p. 3-32.
22. Khan SR, Thamilselvan S. Nephrolithiasis: Consequence of renal epithelial cell exposure to oxalate and calcium crystals. Molecular Urology 2000;4:305-11.
23. Kok DJ. Intratubular crystallisation events. World J Urol 1997;15:219-28.
24. Lieske JC, Toback FG. Interaction of urinary crystals with renal epithelial cells in the pathogenesis of nephrolithiasis. Semin Nephrol 1996;16:458-73.
25. Tiselius HG, Hojgaard I. Some aspects of the intratubular precipitation of calcium salts. J Am Soc Nephrol 1999;10:371-5.
26. Verkoelen CF, van der Boom BG, Schröder FH, Romijn JG. Cell cultures and nephrolithiasis. World J Urol 1997;157:376-83.
27. Werness PG, Bergert JH, Smith LH. Crystalluria. J Cryst Growth 1981;53:166-81.
28. Coe FL, Parks JH. Defences of an unstable compromise: Crystallization inhibitors and the kidney's role in mineral regulation. Kidney Int 1990;38:625-31.
29. Coe FL, Parks JH, Nakagawa Y. Protein inhibitors of cystallization. Semin Nephrol 1991;11:98-109.
30. Crassweller PO, Brandes L, Katirzoglou A, Oreopoulos DG. Studies on crystalluria in recurrent calcium lithiasis. Can J Surg 1979;22:527-9.
31. Fleisch H. Role of inhibitors and promoters of crystal nucleation, growth and aggregation in the formation of calcium stones. In: Wickham JEA, Buck AC, editors. Renal Tract Stone. Metabolic Basis and Clinical Practice. Edinburgh (UK): Churchill Livingston; 1990. p. 295-306.
32. Hess B, Meinhardt U, Zipperle L, Giovanoli R, Jaeger P. Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: Impact of various modifiers. Urol Res 1995;23:231-8.
33. Lieske JC, Coe FL. Urinary inhibitors and renal stone formation. In: Coe FL, Pak CYC, Parks JH, Preminger GM, editors. Kidney Stones - Medical and Surgical Management. Philadelphia: Lippincott-Raven publishers; 1996. p. 65-113.
34. Robertson WG, Peacock M. Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone formers. Clin Sci 1972;43:499-506.
35. Romberg RW, Werness PG, Riggs BL, Mann KG. Inhibition of hydroxyapatite crystal growth by bone-specific and other calcium-binding proteins. Biochemistry 1986;25:1176-80.
36. Ryall RL. Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol 1997;15:155-64.
37. Zerwkh JE, Hwang TIS, Pointdexter J, Hill K, Wedell G, Pak CYC. Modulation by calcium of the inhibitor activity of naturally occurring urinary inhibitors. Kidney Int 1998;33:1005-8.
38. Deganello S, Asplin J, Coe FL. Evidence that tubule fluid in the thin segment of the loop of Henle normally is supersaturated and forms poorly crystallized hydroxyapatite that can initiate renal stones. Kidney Int 1990;37:472.
39. Höjgaard I, Tiselius HG. Crystallization in the nephron. Urol Res 1999;27:397-403.
40. Lupták I, Bek-Jensen H, Fornander A-M, Höjgaard I, Nilsson M-A, Tiselus HG. Crystallization of calcium oxalate and calcium phosphate at supersaturation levels corresponding to those in different parts of the nephron. Scanning Microsc 1994;8:47-62.
41. Brien G, Schubert G, Bick C. 10,000 Analyses of urinary calculi using X-ray diffraction and polarizing microscopy. Eur Urol 1982;8:251-6.
42. Herring LC. Observations on the analysis of ten thousand urinary calculi. J Urol 1962;88:545-62.
43. Samuell CT, Kasidas GP. Biochemical investigations in renal stone formers. Ann Clin Biochem 1995;32:112-22.
44. Hesse A, Tiselius HG, Jahnen A. Urinary Stones: Diagnosis, Treatment and Prevention of Recurrence. Basel (CH): S. Karger; 1997. p. 24-202.
45. Tiselius HG and coworkers of the Advisory Board of European Urolithiasis Research and Health Care Office Working Party for lithiasis. Possibilities for preventing recurrent calcium stone formation: Principles for the metabolic evaluation for patients with calcium stone disease. BJU Int 2001;88:158-68.
46. Tiselius HG, Ackermann D, Alken P, Buck C, Conort P, Gallucci M. Guidelines on urolithiasis. EAU Working Party on Lithiasis. Eur Urol 2001;40:362-71.
47. Tiselius HG. Recurrent stone formation in patients treated with ESWL. J Stone Dis 1992;4:152-7.
48. Leusmann DB, Niggemann H, Roth S, von Ahlen H. Recurrence rates and severity of urinary calculi. Scand J Urol Nephrol 1995;29:279-83.
49. Griffith DP, Osborne CA. Infection (urease) stones. Miner Electrolyte Metab 1987;13:278-85.
50. Hugosson J, Grenabo L, Hedelin H, Pettersson S, Seeberg S. Bacteriology of upper urinary tract stones. J Urol 1990;143:965-8.
51. Lerner SP, Gleeson MJ, Griffith DP. Infection stones. J Urol 1989;141:753-8.
52. Brand M, Harris MM, Biloon S. Cystinuria. Excretion of a cystine complex which decomposes in urine with the liberation of free cysteine. J Biol Chem 1930;88:315.
53. Ramakumar S, Patterson DE, LeRoy AJ, Bender CE, Erickson SB, Wilson DM, et al. Prediction of stone composition from a plain radiograph: A prospective study. J Endourol 1999;13:397-401.
54. Preminger GM, Vieweg J, Leder RA, Nelson RC. Urolithiasis: Detection and management with unenhanced spiral CT - A urologic perspective. Radiology 1998;207:308-9.
55. Smith RC, Verga M, Dalrymple N, McCarthy S, Rosenfield AT. Acute ureteral obstruction: Value of secondary signs of helical unenhanced CT. Am J Radiol 1996;167:1109-13.
56. Böhles H, Beifuss OJ, Brandl U, Pichl J, Akçetin Z, Demling L. Urinary factors of kidney stone formation in patients with Crohn's disease. Klin Wochenschr 1988;66:87-91.
57. Brown JM, Chalmers AH, Cowley DM, McWhinney BC. Enteric hyperoxaluria and urolithiasis. N Engl J Med 1986;32:2073-4.
58. Dobbins JW. Nephrolithiasis and intestinal disease. J Clin Gastroenterol 1985;7:21-4.
59. Hessov I, Holm CN, Hansen LP. Relationship between dietary calcium and hyperoxaluria after intestinal shunt operation for obesity. Digestion 1978;17:268-71.
60. McLeod RS, Churchill DN. Urolithiasis complicating inflammatory bowel disease. J Urol 1992;148:974-8.
61. Tiselius HG, Ahlstrand C, Nilsson MA, Lundström B. 14C oxalate absorption by normal persons, calcium oxalate stone formers, and patients with surgically disturbed intestinal function. Clin Chem 1981;27:1682-5.
62. Buck AC. Hypercalciuria in idiopathic calcium oxalate urolithiasis. In: Wickham JEA, Buck AC, editors. Renal Tract Stone: Metabolic Basis and Clinical Practice. Edinburgh (UK): Churchill Livingstone; 1990. p. 239-51.
63. Pak CYC. The spectrum and pathogenesis of hypercalciuria. Urol Clin North Am 1981;8:245-52.
64. Cupisti A, Morelli E, Meola M, Cozza V, Parrucci M, Barsotti G. Hypertension in kidney stone patients. Nephrology 1996;76:569-72.
65. Backman U, Danielson BG, Johansson G, Ljunghall S, Wikström B. Incidence and clinical importance of renal tubular defects in recurrent renal stone formers. Nephron 1980;25:96-101.
66. Penney MD, Oleesky DA. Renal tubular acidosis. Ann Clin Biochem 1999;36:408-22.
67. Singh PP, Pendse AK, Ahmed A, Ramvataram DVSS, Rajpurohit SK. A study of recurrent stone formers with special reference to renal tubular acidosis. Urol Res 1995;23:201-3.
68. Coe FL. Uric acid and calcium oxalate nephrolithiasis. Kidney Int 1983;24:392-403.
69. Rodman JS, Sosa RE, Lopez MA. Diagnosis and treatment of uric acid calculi. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, editors. Kidney stones - Medial and surgical management. Philadelphia: Lippincott-Raven publishers; 1996. p. 973-89.
70. Higashihara E, Nutahara K, Takeuchi T, Shoji N, Araie M, Aso Y. Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: Responses to citrate. J Urol 1991;145:942-8.
71. Ahlstrand C, Tiselius HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987;21:225-8.
72. Pak CYC. Citrate and renal calculi. Mineral Eletrolyte Metabolism 1987;13:257-66.
73. Hatch M, Mulgrew S, Bourke E, Keogh B, Costello J. Effect of megadoses of ascorbic acid on serum and urinary oxalate. Eur Urol 1980;6:166-9.
74. Urivetzky M, Kessaris D, Smith AD. Ascorbic acid overdosing: A risk factor for calcium oxalate nephrolithiasis. J Urol 1992;147:1512-8.
75. Leigh Auer B, Auer D, Rodgers AL. The effect of ascorbic acid ingestion on the biochemical and physiochemical risk factors associated with calcium oxalate kidney stone formation. Clin Chem Lab Med 1998;36:143-8.
76. Traxer O, Adams-Huet B, Pak CYC, Pearle MS. Risk of calcium oxalate stone formation with ascorbic acid ingestion. Abstract 1001. J Urol 2001;165:243.
77. Wandzilak TR, Dándre SD, Davis PA, Williams HE. Effect of high dose vitamin C on urinary oxalate levels. J Urol 1994;151:834-7.
78. Hess B. Drug-induced urolithiasis. Current Opinion in Urology 1998;8:331-4.
79. Sundaram CP, Saltzman B. Urolithiasis associated with protease inhibitors. J Endourol 1999;13:309-12.
80. Hess B. Bad dietary habits and recurrent calcium oxalate nephrolithiasis. Nephrol Dial Transplant 1998;13:1033-8.
81. Hiatt RA, Ettinger B, Coan B, Quesenberg Jr CP, Duncan D, Citron JT. Randomised controlled trial of low animal protein, High fiber diet in prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25-33.
82. Hallson PC, Kasidas GP. Hyperoxaluria in calcium oxalate urolithiasis. In: Wickham JEA, Buck AC, editors. Renal Tract Stone. Metabolic Basis and Clinical Practice. Edinburgh (UK): Churchill Livingstone; 1990. p. 271-84.
83. Hatch M. Oxalate status in stone formers. Two distinct hyperoxaluric entities. Urol Res 1993;21:55-9.
84. Holmes RP, Assimos DG, Goodman HO. Genetic and dietary influences on urinary oxalate excretion. Urol Res 1998;26:195-200.
85. Robertson WG. Mild hyperoxaluria: A critical review and future outlook. In: Borghi L, Meschi T, Briganti A, Schianchi T, Novarini A, editors. Kidney Stones. Cosenza (Italy): Editorial Bios; 1999. p. 33-42.
86. Trinchieri A, Ostini F, Nespoli R, Rovera F, Zanetti G, Pisani E. Hyperoxaluria in patients with idiopathic calcium nephrolithiasis. J Nephrol 1998;11(Suppl 1):70-2.
87. Marangella A, Vitale C, Bagnis C, Bruno M, Ramello A. Idiopathic calcium nephrolithiasis. Nephron 1999;81(Suppl 1):38-44.
88. Buck AC, Lote CJ. The renal handling of calcium. In: Wickham JEA, Buck AC, editors. Renal Tract Stone: Metabolic Basis and Clinical Practice. Edinburgh (UK): Churchill-Livingstone; 1990. p. 165-82.
89. Lingeman JE, Smith LH, Woods JR, Newman DM, editors. Metabolic evaluation and treatment of the stone patient. In: Urinary Calculi: ESWL, Endourology and Medical Therapy. Philadelphia: Lea & Febiger; 1989. p. 84-133.
90. Lim P, Jacob E. Magnesium deficiency in patients on long-term diuretic therapy for heart failure. BMJ 1972;3:620-2.
91. Elliot JS, Sharp RF, Lewis L. Urinary pH. J Urol 1959;81:339-43.
92. Gault MH, Chafe L. First morning urine pH in the diagnosis of renal tubular acidosis with nephrolithiasis. Clin Nephrol 1994;41:59-62.
93. Osther PJ, Hansen AB, Rohl HF. Screening renal stone formers for distal renal tubular acidosis. Br J Urol 1989;63:581-3.
94. Tiselius HG. Stone incidence and prevention. Braz. J Urol 2000;26:452-62.
95. Reference deleted in proof.
96. Berg C, Larsson L, Tiselius HG. The composition of four-hour urine samples from patients with calcium oxalate stone disease. Br J Urol 1987;60:301-6.
97. Strohmaier WL, Holez K-J, Bichler KH. Spot urine samples for the metabolic evaluation of urolithiasis patients. Eur Urol 1997;32:294-300.
98. Pak CYC. General guidelines in medical evaluation. In: Resnick MI, Pak CYC, editors. Urolithiasis. A Medical and Surgical Reference. Philadelphia: WB Saunders Company; 1990. p. 153-72.
99. Tiselius HG. Standardized estimate of the ion-activity product of calcium oxalate in urine from renal stone formers. Eur Urol 1989;16:48-58.
100. Ashby R, Gybry AZ. A thermodynamic equilibrium model for calcium salt urolithiasis: Clinical application. Exp Nephrol 1997;5:246-52.
101. Tiselius HG. Estimated levels of supersaturation with calcium phosphate and calcium oxalate in the distal tubule. Urol Res 1997;25:153-9.
102. Mitch WE, Walser M. Nutritional therapy of the uremic patient. In: Brenner BM, Rector FC Jr, editors. The Kidney. 3rd Edition. Philadelphia: WB Saunders; 1986. p. 1759-90.
103. Sakahee K, Nicar M, Hill K, Pak CYC. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone forming salts. Kidney Int 1983;24:348-52.
104. Bek-Jensen H, Tiselius HG. Repeated urine analysis in patients with calcium stone disease. Eur Urol 1998;33:323-32.
105. Hess B, Hasler-Strub U, Ackerman D, Jaeger PH. Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis. Nephrol Dial Transplant 1997;12:1362-8.
106. Höbarth K, Hofbauer J, Szabo N. Value of repeated analysis of 24-hour urine in recurrent calcium urolithiasis. Urology 1994;44:20-5.
107. Pak CYC, Peterson R, Pointdexter JR. Adequacy of a single stone risk analysis in the medical evaluation of urolithiasis. J Urol 2000;165:378-81.
108. Robertson WG, Peacock M, Nordin BEC. Activity products in stone-forming and nonstone-forming urine. Clin Sci 1968;34:579-94.
109. Breslau NA. Pathogenesis and management of hypercalciuric nephrolithiasis. Mineral Electrolyte Metab 1994;20:328-39.
110. Pak CYC, editor Hypercalciurias. In: Calcium Urolithiasis. New York: Plenum Medical Book Company; 1978. p. 37-79.
111. Backman U. Kidney Function in Recurrent Renal Stone Formers. Uppsala (Sweden): Uppsala University; 1976. p. 8. [Dissertation].
112. Ahlstrand C, Tiselius HG. Recurrences during a 10-year follow-up after first renal stone episode. Urol Res 1990;18:397-9.
113. Strohmaier WL. Course of calcium stone disease without treatment. What can we expect? Eur Urol 2000;37:339-44.
114. Tiselius HG. Factors influencing the course of calcium oxalate stone disease. Eur Urol 1999;36:363-70.